Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

被引：0
|
作者：
Zeqing Zhang
Xi Chen
Puhan Lu
Jianhua Zhang
Yongping Xu
Wentao He
Mengni Li
Shujun Zhang
Jing Jia
Shiying Shao
Junhui Xie
Yan Yang
Xuefeng Yu
机构：
[1] Huazhong University of Science and Technology,Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Glucagon-like peptide-1 agonists; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Cardiovascular outcomes; Acute pancreatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 31 条
  • [21] Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
    Dan Liu
    Biao Jin
    Wei Chen
    Peng Yun
    BMC Pharmacology and Toxicology, 20
  • [22] Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
    Liu, Dan
    Jin, Biao
    Chen, Wei
    Yun, Peng
    BMC PHARMACOLOGY & TOXICOLOGY, 2019, 20 (1)
  • [23] A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
    Poonawalla, Insiya B.
    Bowe, Andy T.
    Tindal, Michael C.
    Meah, Yunus A.
    Schwab, Phil
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 175
  • [24] GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
    Granata, Antonio
    Maccarrone, Rosario
    Anzaldi, Massimiliano
    Leonardi, Giuseppe
    Pesce, Francesco
    Amico, Francesco
    Gesualdo, Loreto
    Corrao, Salvatore
    CLINICAL KIDNEY JOURNAL, 2022, 15 (09) : 1657 - 1665
  • [25] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
    Parab, Panah
    Chaudhary, Priti
    Mukhtar, Sonia
    Moradi, Ali
    Kodali, Athri
    Okoye, Chiugo
    Klein, Dhadon
    Mohamoud, Iman
    Olanisa, Olawale O.
    Hamid, Pousette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [26] The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
    Kanozawa, Koichi
    Noguchi, Yuichi
    Sugahara, Souichi
    Nakamura, Satoko
    Yamamoto, Hirohisa
    Kaneko, Keiko
    Kono, Rika
    Sato, Saeko
    Ogawa, Tomonari
    Hasegawa, Hajime
    Katayama, Shigehiro
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (04) : 825 - 834
  • [27] The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
    Pan, Xiaohui
    Xu, Shishi
    Li, Juan
    Tong, Nanwei
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [28] Effect of 3-month therapy with SGLT-2 inhibitors and GLP-1 agonists on ambulatory blood pressure in patients with type 2 diabetes mellitus
    Papazafiropoulou, Athanasia
    Papantoniou, Styliani
    Rallatou, Maria
    Melidonis, Andreas
    Antonopoulos, Stavros
    SCIENTIFIC CHRONICLES, 2020, 25 (03) : 528 - 536
  • [29] Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
    Tsai, Chia-Jen
    Tsao, Cheng-Feng
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [30] Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis
    Wang, Siwen
    Wu, Ting
    Zuo, Zhihong
    Jin, Ping
    Luo, Xuan
    Deng, Meichun
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (16) : 1840 - 1849
1234